DKD and CV risk: What is the potential of targeting GLP-1?
Video navigation menu
- CVD risk in DKD patients 00:45
- What drives residual CV risk in DKD? 03:25
- Novel opportunities - anti-inflammatory strategies 05:31
- Novel opportunities - targeting calcification 09:54
- Mechanisms of CV benefit by GLP-1RAs 11:37
What is/are potential mechanism(s) for CV benefit by GLP-1RAs?
- A. Improved glycemic control but unchanged lipid levels
- B. GLP-1RA may upregulate expression of TNFα in the heart
- C. Activation of GLP-1 on macrophages drives them into the active state (M1)
- D. Dose-dependent weight reduction and lowering of blood pressure
This lecture by prof. Erik Stroes was part of the EBAC-accredited symposium "Cardiorenal cross-talk in diabetes: The preventive challenge in DKD for GLP-1RA" held during ERA EDTA Virtual Congress 2020.
Prof. Erik Stroes, MD - Professor of Vascular Medicine, Amsterdam University Medical Centers, Amsterdam, The Netherlands
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from Novo Nordisk A/S.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: